Literature DB >> 16028778

Resolution of neurogenic arterial hypertension after suboccipital decompression for Chiari malformation. Case report.

Sait Naderi1, Feridun Acar, Göksemin Acar, Süleyman Men.   

Abstract

A Chiari malformation Type I may remain asymptomatic until the patient has reached adulthood and acute presentation of symptoms occurs. In several clinical and experimental studies it has been shown that essential hypertension is associated with vascular compression of the brainstem, particularly of the rostral ventrolateral medulla oblongata. Nevertheless, two cases of Chiari malformation and neurogenic arterial hypertension have been reported. In this article the authors describe a patient with Chiari malformation Type I and neurogenic arterial hypertension. A simple suboccipital decompression not only provided neurological improvement, but also led to resolution of the hypertension. In cases of Chiari malformation and concomitant neurogenic arterial hypertension, careful preoperative clinical and neuroimaging assessments may reveal the cause of the arterial hypertension. Resolution of neurogenic arterial hypertension may be expected even in a case of simple suboccipital decompression.

Entities:  

Mesh:

Year:  2005        PMID: 16028778     DOI: 10.3171/jns.2005.102.6.1147

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  3 in total

1.  Clinical diagnosis-part II: what is attributed to Chiari I.

Authors:  Federica Novegno
Journal:  Childs Nerv Syst       Date:  2019-05-15       Impact factor: 1.475

2.  Normalization of systemic arterial hypertension following removal of posterior fossa hemangioblastoma: a case report.

Authors:  Hooshang Saberi; Ali Tayebi Meybodi; Mehdi Zeinalizadeh
Journal:  Cases J       Date:  2009-04-29

3.  Is Chiari malformation a cause of systemic hypertension and sinus bradycardia? A case report and literature review.

Authors:  Majid Ghasemi; Khodayar Golabchi; Vahid Shaygannejad; Majid Rezvani
Journal:  J Res Med Sci       Date:  2011-01       Impact factor: 1.852

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.